Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn

Global pharma major Lupin has spun-out two oncology programmes to Kaveri Therapeutics Inc for $1..6 million, taking its stake in the U.S. clinical-stage oncology company to 82.2%.

Its wholly-owned US subsidiary Lupin Inc (LI), which has entered into a licensing arrangement with Kaveri to grant exclusive perpetual license for two of its oncology programmes — LNP7457 (PRMT5) and LNP8701 (SOS1) — will provide seed funding to Kaveri. LI has received 332,000 common shares (82.2% equity stake) in Kaveri, in exchange of license, the company said in its regulatory filing.

Kaveri will advance the programme through global clinical trials. It will also raise additional capital to fund the clinical development efforts. The clinical-stage oncology company was incorporated this May to focus on the early-stage clinical development of therapies for solid tumors, including lung, pancreatic, ovarian, and CNS-related cancers.

Both the oncology programmes demonstrated encouraging clinical progress and reported positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively, Lupin said, announcing signing of a licensing agreement to grant an exclusive perpetual licence to Kaveri.

“Proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics,” Lupin CEO Vinita Gupta said.